Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
An insider of CTNM has filed a notice of intent to sell shares. The filing covers 4,170 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $59,964.60 and 23,099,173 shares outstanding.
The shares were originally acquired as 4,170 restricted stock units from the issuer on May 9, 2017. The same account has sold 4,170 shares on December 23, 2025 for $51,009.11 and another 4,170 shares on January 5, 2026 for $43,543.06 under a Rule 10b5‑1 trading plan for Daniel Lorrain.
Contineum Therapeutics reported that its General Counsel and Corporate Secretary, John Stephen Healy, received a grant of stock options on January 30, 2026. The award covers 206,411 shares of Class A common stock at an exercise price of $14.26 per share.
The options were granted under the company’s 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, conditioned on Healy’s continued service with the company. Following this grant, he beneficially owns 206,411 stock options, held directly.
Contineum Therapeutics reported a new equity award for its Chief Financial Officer, Peter Slover. On 01/30/2026, he received a grant of stock options to buy 192,000 shares of Class A common stock at an exercise price of $14.26 per share under the company’s 2024 Equity Incentive Plan. These options vest in equal monthly installments over 48 months, conditioned on his continuous service, and he beneficially owns 192,000 derivative securities directly after the grant.
Contineum Therapeutics, Inc. granted CEO and President Carmine N. Stengone a stock option award on January 30, 2026 under its 2024 Equity Incentive Plan. The grant covers 445,000 stock options with an exercise price of $14.26 per share.
The options relate to Class A common stock and vest in equal monthly installments over 48 months, as long as Mr. Stengone continues in service. The options expire on January 29, 2036, and all 445,000 derivative securities are reported as directly owned following the grant.
Contineum Therapeutics granted stock options to Chief Scientific Officer Lorrain Daniel S. on January 30, 2026 under its 2024 Equity Incentive Plan. The award covers options to buy 160,000 shares of Class A common stock at an exercise price of $14.26 per share, expiring on January 29, 2036. These options vest in equal monthly installments over 48 months, conditioned on the executive’s continued service.
An additional grant of stock options to purchase 6,500 shares of Class A common stock at $14.26 per share was made in connection with the continuous service of the executive’s spouse at the company. These options have the same 48‑month monthly vesting schedule and are reported as indirectly owned through the spouse.
Contineum Therapeutics executive Tim Watkins reported option exercises, share sales, and a new option grant. On 01/28/2026 he exercised 3,611 stock options at an exercise price of $4.50 per share, acquiring 3,611 shares of Class A common stock.
That same day, he sold 2,800 shares at a weighted average price of $14.0861 and 811 shares at a weighted average price of $14.4848, leaving no directly held common shares after the transactions. These sales were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.
In a separate transaction on 01/30/2026, Watkins received an award of 160,000 stock options with a $14.26 exercise price, expiring on 01/29/2036. These options vest in equal monthly installments over 48 months, subject to his continuous service.
Contineum Therapeutics, Inc. received an amended Schedule 13G/A showing that investment manager Franklin Advisers, Inc., a subsidiary of Franklin Resources, reports beneficial ownership of 1,879,367 shares of Class A common stock, representing 6.2% of the class.
Franklin Advisers has sole voting and sole dispositive power over these shares, which are held in client accounts, including investment companies and other managed portfolios. The filing states the position is held in the ordinary course of business and is not for the purpose of changing or influencing control of Contineum Therapeutics.
Contineum Therapeutics, Inc. adopted a 2026 Employment Inducement Equity Incentive Plan, initially reserving 750,000 shares of its Class A common stock for awards.
The plan’s terms are described as substantially similar to the company’s 2024 Equity Incentive Plan, except that incentive stock options cannot be issued and awards may only be granted to recipients eligible under applicable Nasdaq rules. It was approved by the Board without stockholder approval under Nasdaq Listing Rule 5635(c)(4).
Awards may be granted only to new employees or rehires in connection with the commencement of employment when the grant is an inducement material to joining the company. Full plan documents and related stock option and restricted stock unit agreement forms will be filed as exhibits to the company’s Form 10-K for the year ended December 31, 2025.
Contineum Therapeutics, Inc. completed an underwritten public offering of 7,346,938 shares of its Class A common stock at $12.25 per share. The underwriters purchased the shares at $11.515 per share, and Contineum estimates net proceeds of approximately $84.2 million, assuming no exercise of the underwriters’ option to buy more shares. The company granted the underwriters a 30-day option to purchase up to an additional 1,102,040 shares. The transaction was conducted under an effective Form S-3 shelf registration and closed on December 15, 2025.
Contineum also issued press releases announcing a proposed $75.0 million offering and the pricing of an upsized $90.0 million offering of Class A common stock, highlighting increased deal size as demand solidified.
Contineum Therapeutics, Inc. is offering 7,346,938 shares of its Class A common stock at a public price of $12.250 per share, for gross proceeds of $89,999,991 before fees and expenses. After underwriting discounts and estimated costs, the company expects net proceeds of approximately $84.2 million, or approximately $96.9 million if underwriters fully exercise their 30‑day option to buy up to 1,102,040 additional shares.
Contineum is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation and immunology, including lead candidates PIPE‑791 and PIPE‑307. It plans to use the cash, together with existing balances, to advance PIPE‑791, support other research and development, and for general corporate purposes, including potential acquisitions. After this offering, 30,446,111 shares of Class A common stock (or 31,548,151 shares if the option is fully exercised) and 6,083,338 shares of non‑voting Class B common stock will be outstanding, and the company believes this funding will support operations through mid‑2029.